rEEcur: This phase II/III trial is comparing four widely used chemotherapy regimens for patients with primary refractory and recurrent Ewing SarcomaInternational Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

Summary

In this trial, patients will be randomised to one of four chemotherapy regimens in order to identify which treatment is the best fit for future use. All four arms are currently standard of care treatment options and will be administered as follows: (Arm 1) Topotecan and Cyclophosphamide (TC): 6 cycles of 21 days, additional cycles at clinician's discretion. IV Infusoion of Topotecan 0.75mg/m2 and Cyclophosphamide 250mg/m2 on day 1, 2, 3, 4, 5. (Arm 2) Irinotecan and Temozolomide (IT): 6 cycles of 21 days, additional cycles at clinician's discretion. IV infusion of Irinotecan 50mg/m2 on days 1, 2, 3, 4, 5 Temozolomide 100mg/m2 orally on days 1, 2, 3, 4, 5 (Arm 3) Gemcitabine and Docetaxel (GD): 6 cycles of 21 days, additional cycles at clinician's discretion. IV infusion of Gemcitabine 900mg/m2 on days 1, 8. IV infusion of Docetxal 800mg/m2 on day 8. (Arm 4) High dose Ifosfamide (IFOS): 4 cycles of 21 days. IV infusion of Ifosfamide 3g/m2 on days 1, 2, 3, 4, 5.

Conditions

This trial is treating patients with Ewing Sarcoma.

More information